Madrigal Pharmaceuticals Inc’s recent filing unveils that its Senior VP, Chief Pharma Dev. Waltermire Robert E. unloaded Company’s shares for reported $4.82 million on Mar 05 ’25. In the deal valued at $341.32 per share,14,113 shares were sold. As a result of this transaction, Waltermire Robert E. now holds 3,728 shares worth roughly $1.25 million.
Then, Kelley Shannon T sold 415 shares, generating $139,025 in total proceeds. Upon selling the shares at $335.00, the General Counsel now owns 7,290 shares.
Before that, Dier Mardi sold 1,961 shares. Madrigal Pharmaceuticals Inc shares valued at $637,248 were divested by the SVP and CFO at a price of $324.96 per share. As a result of the transaction, Dier Mardi now holds 6,914 shares, worth roughly $2.32 million.
B. Riley Securities upgraded its Madrigal Pharmaceuticals Inc [MDGL] rating to a Buy from a a Neutral in a research note published on February 28, 2025; the price target was increased to $422 from $236. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in late February has reiterated a ‘”a Buy”‘ rating for it. Cantor Fitzgerald began covering MDGL with “Neutral” recommendation on June 28, 2024. Wolfe Research started covering the stock on June 11, 2024. It rated MDGL as “an Outperform”.
Price Performance Review of MDGL
On Tuesday, Madrigal Pharmaceuticals Inc [NASDAQ:MDGL] saw its stock jump 1.89% to $335.39. Over the last five days, the stock has gained 4.38%. Madrigal Pharmaceuticals Inc shares have risen nearly 8.69% since the year began. Nevertheless, the stocks have risen 33.61% over the past one year. While a 52-week high of $377.46 was reached on 02/26/25, a 52-week low of $189.00 was recorded on 01/15/25. SMA at 50 days reached $324.91, while 200 days put it at $280.41.
Levels Of Support And Resistance For MDGL Stock
The 24-hour chart illustrates a support level at 321.53, which if violated will result in even more drops to 307.68. On the upside, there is a resistance level at 342.73. A further resistance level may holdings at 350.08. The Relative Strength Index (RSI) on the 14-day chart is 51.38, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.77, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 54.01%. Stochastics %K at 41.63% indicates the stock is a holding.
The most recent change occurred on April 22, 2024 when BofA Securities began covering the stock and recommended ‘”an Underperform”‘ rating along with a $150 price target.
